IgA nephropathy

IgA nephropathy (IgAN) is the most frequent primary form of glomerulonephritis. The origin of IgAN is only partially understood and appears to involve the occurrence of IgA , which is normally secreted by mucous membranes, in the circulation followed by its glomerular deposition and inflammatory cha...

Full description

Saved in:
Bibliographic Details
Published in:Urologie (Heidelberg, Germany) Germany), 2024-01, Vol.63 (1), p.103
Main Author: Floege, Jürgen
Format: Article
Language:ger
Subjects:
Adrenal Cortex Hormones - therapeutic use
Budesonide - adverse effects
Glomerulonephritis, IGA - diagnosis
Humans
Kidney Glomerulus - pathology
Proteinuria - chemically induced
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IgA nephropathy (IgAN) is the most frequent primary form of glomerulonephritis. The origin of IgAN is only partially understood and appears to involve the occurrence of IgA , which is normally secreted by mucous membranes, in the circulation followed by its glomerular deposition and inflammatory changes. Clinically, IgAN mostly follows an inapparent course and the disease is often only first diagnosed by kidney biopsy when kidney function disorders are already manifested. Key prognostic indicators include the extent of proteinuria and the already manifested evidence of irreversible kidney damage. Treatment includes supportive measures. The effectiveness of high-dose systemic corticosteroid treatment in European patients is uncertain and controversial due to the adverse side effects. Nefecon (encapsulated budesonide) is the first specific drug licensed for treatment of high risk IgAN patients. A number of further approaches are currently in clinical trials.
ISSN:2731-7072
DOI:10.1007/s00120-023-02268-1